35189854|t|Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset.
35189854|a|BACKGROUND: Prior studies on the role of gut-microbiome in Amyotrophic Lateral Sclerosis (ALS) pathogenesis have yielded conflicting results. We hypothesized that gut- and oral-microbiome may differentially impact two clinically-distinct ALS subtypes (spinal-onset ALS (sALS) vs. bulbar-onset ALS (bALS), driving disagreement in the field. METHODS: ALS patients diagnosed within 12 months and their spouses as healthy controls (n = 150 couples) were screened. For eligible sALS and bALS patients (n = 36) and healthy controls (n = 20), 16S rRNA next-generation sequencing was done in fecal and saliva samples after DNA extractions to examine gut- and oral-microbiome differences. Microbial translocation to blood was measured by blood lipopolysaccharide-binding protein (LBP) and 16S rDNA levels. ALS severity was assessed by Revised ALS Functional Rating Scale (ALSFRS-R). RESULTS: sALS patients manifested significant gut-dysbiosis, primarily driven by increased fecal Firmicutes/Bacteroidetes-ratio (F/B-ratio). In contrast, bALS patients displayed significant oral-dysbiosis, primarily driven by decreased oral F/B-ratio. For sALS patients, gut-dysbiosis (a shift in fecal F/B-ratio), but not oral-dysbiosis, was strongly associated with greater microbial translocation to blood (r = 0.8006, P < 0.0001) and more severe symptoms (r = 0.9470, P < 0.0001). In contrast, for bALS patients, oral-dysbiosis (a shift in oral F/B-ratio), but not gut-dysbiosis, was strongly associated with greater microbial translocation to blood (r = 0.9860, P < 0.0001) and greater disease severity (r = 0.9842, P < 0.0001). For both ALS subtypes, greater microbial translocation was associated with more severe symptoms (sALS: r = 0.7924, P < 0.0001; bALS: r = 0.7496, P = 0.0067). Importantly, both sALS and bALS patients displayed comparable oral-motor deficits with associations between oral-dysbiosis and severity of oral-motor deficits in bALS but not sALS. This suggests that oral-dysbiosis is not simply caused by oral/bulbar/respiratory symptoms but represents a pathological driver of bALS. CONCLUSIONS: We found increasing gut-dysbiosis with worsening symptoms in sALS patients and increasing oral-dysbiosis with worsening symptoms in bALS patients. Our findings support distinct microbial mechanisms underlying two ALS subtypes, which have been previously grouped together as a single disease. Our study suggests correcting gut-dysbiosis as a therapeutic strategy for sALS patients and correcting oral-dysbiosis as a therapeutic strategy for bALS patients.
35189854	14	23	dysbiosis	Disease	MESH:D064806
35189854	71	74	ALS	Disease	MESH:D000690
35189854	87	90	ALS	Disease	MESH:D000690
35189854	218	247	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
35189854	249	252	ALS	Disease	MESH:D000690
35189854	397	400	ALS	Disease	MESH:D000690
35189854	424	427	ALS	Disease	MESH:D000690
35189854	429	433	sALS	Disease	MESH:D000690
35189854	452	455	ALS	Disease	MESH:D000690
35189854	457	461	bALS	Disease	MESH:D000690
35189854	508	511	ALS	Disease	MESH:D000690
35189854	512	520	patients	Species	9606
35189854	632	636	sALS	Disease	MESH:D000690
35189854	641	645	bALS	Disease	MESH:D000690
35189854	646	654	patients	Species	9606
35189854	894	928	lipopolysaccharide-binding protein	Gene	3929
35189854	930	933	LBP	Gene	3929
35189854	956	959	ALS	Disease	MESH:D000690
35189854	993	996	ALS	Disease	MESH:D000690
35189854	1042	1046	sALS	Disease	MESH:D000690
35189854	1047	1055	patients	Species	9606
35189854	1083	1092	dysbiosis	Disease	MESH:D064806
35189854	1187	1191	bALS	Disease	MESH:D000690
35189854	1192	1200	patients	Species	9606
35189854	1228	1237	dysbiosis	Disease	MESH:D064806
35189854	1289	1293	sALS	Disease	MESH:D000690
35189854	1294	1302	patients	Species	9606
35189854	1308	1317	dysbiosis	Disease	MESH:D064806
35189854	1361	1370	dysbiosis	Disease	MESH:D064806
35189854	1535	1539	bALS	Disease	MESH:D000690
35189854	1540	1548	patients	Species	9606
35189854	1555	1564	dysbiosis	Disease	MESH:D064806
35189854	1606	1615	dysbiosis	Disease	MESH:D064806
35189854	1776	1779	ALS	Disease	MESH:D000690
35189854	1864	1868	sALS	Disease	MESH:D000690
35189854	1894	1898	bALS	Disease	MESH:D000690
35189854	1943	1947	sALS	Disease	MESH:D000690
35189854	1952	1956	bALS	Disease	MESH:D000690
35189854	1957	1965	patients	Species	9606
35189854	1987	2006	oral-motor deficits	Disease	MESH:D009461
35189854	2038	2047	dysbiosis	Disease	MESH:D064806
35189854	2064	2083	oral-motor deficits	Disease	MESH:D009461
35189854	2087	2091	bALS	Disease	MESH:D000690
35189854	2100	2104	sALS	Disease	MESH:D000690
35189854	2130	2139	dysbiosis	Disease	MESH:D064806
35189854	2176	2187	respiratory	Disease	MESH:D012131
35189854	2237	2241	bALS	Disease	MESH:D000690
35189854	2280	2289	dysbiosis	Disease	MESH:D064806
35189854	2317	2321	sALS	Disease	MESH:D000690
35189854	2322	2330	patients	Species	9606
35189854	2351	2360	dysbiosis	Disease	MESH:D064806
35189854	2388	2392	bALS	Disease	MESH:D000690
35189854	2393	2401	patients	Species	9606
35189854	2469	2472	ALS	Disease	MESH:D000690
35189854	2582	2591	dysbiosis	Disease	MESH:D064806
35189854	2622	2626	sALS	Disease	MESH:D000690
35189854	2627	2635	patients	Species	9606
35189854	2656	2665	dysbiosis	Disease	MESH:D064806
35189854	2696	2700	bALS	Disease	MESH:D000690
35189854	2701	2709	patients	Species	9606

